Literature DB >> 20936883

Methods of model calibration: observations from a mathematical model of cervical cancer.

Douglas C A Taylor1, Vivek Pawar, Denise Kruzikas, Kristen E Gilmore, Ankur Pandya, Rowan Iskandar, Milton C Weinstein.   

Abstract

BACKGROUND: Mathematical models are commonly used to predict future benefits of new therapies or interventions in the healthcare setting. The reliability of model results is greatly dependent on accuracy of model inputs but on occasion, data sources may not provide all the required inputs. Therefore, calibration of model inputs to epidemiological endpoints informed by existing data can be a useful tool to ensure credibility of the results.
OBJECTIVE: To compare different computational methods of calibrating a Markov model to US data.
METHODS: We developed a Markov model that simulates the natural history of human papillomavirus (HPV) infection and subsequent cervical disease in the US. Because the model consists of numerous transition probabilities that cannot be directly estimated from data, calibration to multiple disease endpoints was required to ensure its predictive validity. Goodness of fit was measured as the mean percentage deviation of model-predicted endpoints from target estimates. During the calibration process we used the manual, random and Nelder-Mead calibration methods.
RESULTS: The Nelder-Mead and manual calibration methods achieved the best fit, with mean deviations of 7% and 10%, respectively. Nelder-Mead accomplished this result with substantially less analyst time than the manual method, but required more intensive computing capability. The random search method achieved a mean deviation of 39%, which we considered unacceptable despite the ease of implementation of that method.
CONCLUSIONS: The Nelder-Mead and manual techniques may be preferable calibration methods based on both performance and efficiency, provided that sufficient resources are available.

Entities:  

Mesh:

Year:  2010        PMID: 20936883     DOI: 10.2165/11538660-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  10 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

Authors:  Milton C Weinstein; Bernie O'Brien; John Hornberger; Joseph Jackson; Magnus Johannesson; Chris McCabe; Bryan R Luce
Journal:  Value Health       Date:  2003 Jan-Feb       Impact factor: 5.725

3.  Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty.

Authors:  Nicolas Van de Velde; Marc Brisson; Marie-Claude Boily
Journal:  Am J Epidemiol       Date:  2007-02-01       Impact factor: 4.897

Review 4.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

5.  The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain.

Authors:  N Muñoz; F X Bosch; S de Sanjosé; L Tafur; I Izarzugaza; M Gili; P Viladiu; C Navarro; C Martos; N Ascunce
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

6.  Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia.

Authors:  M H Schiffman; H M Bauer; R N Hoover; A G Glass; D M Cadell; B B Rush; D R Scott; M E Sherman; R J Kurman; S Wacholder
Journal:  J Natl Cancer Inst       Date:  1993-06-16       Impact factor: 13.506

7.  Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001.

Authors:  Vicki B Benard; Christie R Eheman; Herschel W Lawson; Donald K Blackman; Christa Anderson; William Helsel; Sandra F Thames; Nancy C Lee
Journal:  Obstet Gynecol       Date:  2004-03       Impact factor: 7.661

8.  Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia.

Authors:  S K Kjaer; A J van den Brule; J E Bock; P A Poll; G Engholm; M E Sherman; J M Walboomers; C J Meijer
Journal:  Int J Cancer       Date:  1996-03-01       Impact factor: 7.396

9.  Multiparameter calibration of a natural history model of cervical cancer.

Authors:  Jane J Kim; Karen M Kuntz; Natasha K Stout; Salaheddin Mahmud; Luisa L Villa; Eduardo L Franco; Sue J Goldie
Journal:  Am J Epidemiol       Date:  2007-05-25       Impact factor: 4.897

10.  Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK.

Authors:  M Kohli; N Ferko; A Martin; E L Franco; D Jenkins; S Gallivan; C Sherlaw-Johnson; M Drummond
Journal:  Br J Cancer       Date:  2006-12-05       Impact factor: 7.640

  10 in total
  16 in total

1.  Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches.

Authors:  Douglas C A Taylor; Vivek Pawar; Denise T Kruzikas; Kristen E Gilmore; Myrlene Sanon; Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

2.  Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings.

Authors:  April D Kimmel; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman
Journal:  Med Decis Making       Date:  2014-10-20       Impact factor: 2.583

3.  Identifying best-fitting inputs in health-economic model calibration: a Pareto frontier approach.

Authors:  Eva A Enns; Lauren E Cipriano; Cyrena T Simons; Chung Yin Kong
Journal:  Med Decis Making       Date:  2014-05-05       Impact factor: 2.583

4.  Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.

Authors:  Linwei Wang; Emanuel Krebs; Jeong E Min; W Christopher Mathews; Ank Nijhawan; Charurut Somboonwit; Judith A Aberg; Richard D Moore; Kelly A Gebo; Bohdan Nosyk
Journal:  Lancet HIV       Date:  2019-07-11       Impact factor: 12.767

5.  Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions.

Authors:  Olena Mandrik; Chloe Thomas; Sophie Whyte; James Chilcott
Journal:  Pharmacoeconomics       Date:  2022-01-07       Impact factor: 4.558

6.  Microsimulation Model Calibration with Approximate Bayesian Computation in R: A Tutorial.

Authors:  Peter Shewmaker; Stavroula A Chrysanthopoulou; Rowan Iskandar; Derek Lake; Earic Jutkowitz
Journal:  Med Decis Making       Date:  2022-03-21       Impact factor: 2.749

7.  Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities.

Authors:  Xiao Zang; Emanuel Krebs; Jeong E Min; Ankur Pandya; Brandon D L Marshall; Bruce R Schackman; Czarina N Behrends; Daniel J Feaster; Bohdan Nosyk
Journal:  Med Decis Making       Date:  2019-12-22       Impact factor: 2.583

8.  Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Authors:  Bernhard Ultsch; Oliver Damm; Philippe Beutels; Joke Bilcke; Bernd Brüggenjürgen; Andreas Gerber-Grote; Wolfgang Greiner; Germaine Hanquet; Raymond Hutubessy; Mark Jit; Mirjam Knol; Rüdiger von Kries; Alexander Kuhlmann; Daniel Levy-Bruhl; Matthias Perleth; Maarten Postma; Heini Salo; Uwe Siebert; Jürgen Wasem; Ole Wichmann
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

9.  Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.

Authors:  Warner K Huh; Erin Williams; Joice Huang; Tommy Bramley; Nick Poulios
Journal:  Appl Health Econ Health Policy       Date:  2015-02       Impact factor: 2.561

10.  How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value.

Authors: 
Journal:  Int J Drug Policy       Date:  2020-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.